Facebook
Medical Affairs Request Information Prescribing Information Important Safety Information To Patient Site

For adult and pediatric patients with hemophilia A

Help Him REACH HIGHER With Long-lasting Protection

AFSTYLA, with twice-weekly dosing available, delivers long-lasting bleed protection using a novel single-chain design

Explore the benefits of AFSTYLA

2 times weekly

Twice-weekly dosing

FDA approved for 2x–3x weekly dosing
 

View AFSTYLA
steady state data

Zero bleeds (median AsBR*)

ZERO bleeds (median AsBR*)

In all studied populations
 
 

Explore AFSTYLA efficacy

*Annualized spontaneous bleeding rate in clinical trials
(IQR=0–2.4 for patients ≥12 years; 0–2.2 for patients <12 years).

BINDING AFFINITY
STABILIZES FACTOR VIII

Enhanced von Willebrand
factor affinity extends time
in circulation †1

Learn about the
science of AFSTYLA

† As demonstrated in pre-clinical animal studies.

Request information

Have a CSL Behring representative contact you or sign up for updates and information about AFSTYLA

Submit a request

Call AFSTYLA ConnectSM at 1-800-676-4266

A Case Manager is standing by—Monday through Friday, 8am to 8pm ET—to provide you detailed information about services available to your patients.

Have additional questions?

Connect with CSL Behring Medical Affairs to
find additional information and ask questions.

Have additional questions?

Connect with CSL Behring Medical Affairs to
find additional information and ask questions.

Reference: 1. Zollner S, Raquet E, Claar P, et al. Non-clinical pharmacokinetics and pharmacodynamics of rVIII-SingleChain, a novel recombinant single-chain factor VIII. Thromb Res. 2014;134(1):125-131.

You are now leaving the current website.

Do you want to continue?

No Yes